BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 15497763)

  • 1. Serum cholinesterase inhibition by omeprazole and lansoprazole.
    Mequid S; Ramzan I
    Pharmazie; 2004 Sep; 59(9):733. PubMed ID: 15497763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proton pump inhibitors omeprazole and lansoprazole induce relaxation of isolated human arteries.
    Naseri E; Yenisehirli A
    Eur J Pharmacol; 2006 Feb; 531(1-3):226-31. PubMed ID: 16438963
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relaxant effect of omeprazole and lansoprazole in guinea pig gallbladder muscle strips in vitro.
    Aydin C; Sarac B; Koyuncu A; Yildirim S; Sen M; Sarioglu Y
    J Gastroenterol; 2003; 38(8):765-71. PubMed ID: 14505131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of lansoprazole on human leukocyte function.
    Capodicasa E; De Bellis F; Pelli MA
    Immunopharmacol Immunotoxicol; 1999 May; 21(2):357-77. PubMed ID: 10319286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Positive inotropic and negative chronotropic effects of proton pump inhibitors in isolated rat atrium.
    Yenisehirli A; Onur R
    Eur J Pharmacol; 2005 Sep; 519(3):259-66. PubMed ID: 16125697
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antimicrobial actions of benzimidazoles against oral streptococci.
    Nguyen PT; Baldeck JD; Olsson J; Marquis RE
    Oral Microbiol Immunol; 2005 Apr; 20(2):93-100. PubMed ID: 15720569
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of atazanavir oral absorption by lansoprazole gastric acid suppression in healthy volunteers.
    Tomilo DL; Smith PF; Ogundele AB; Difrancesco R; Berenson CS; Eberhardt E; Bednarczyk E; Morse GD
    Pharmacotherapy; 2006 Mar; 26(3):341-6. PubMed ID: 16503713
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner.
    Liu KH; Kim MJ; Jung WM; Kang W; Cha IJ; Shin JG
    Drug Metab Dispos; 2005 Feb; 33(2):209-13. PubMed ID: 15537834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Degradation of lansoprazole and omeprazole in the aquatic environment.
    DellaGreca M; Iesce MR; Previtera L; Rubino M; Temussi F; Brigante M
    Chemosphere; 2006 May; 63(7):1087-93. PubMed ID: 16289231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: similarities and differences among delayed-release proton-pump inhibitor formulations.
    Horn JR; Howden CW
    Aliment Pharmacol Ther; 2005 Dec; 22 Suppl 3():20-4. PubMed ID: 16303033
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of pirenzepine, omeprazole, lansoprazole, and rabeprazole on human neutrophil functions.
    Mikawa K; Akamatsu H; Nishina K; Niwa Y
    Can J Anaesth; 2001 Apr; 48(4):421-2. PubMed ID: 11339790
    [No Abstract]   [Full Text] [Related]  

  • 12. [Suppressive effect of lansoprazole on anti-Candida activity of murine macrophages].
    Motegi H; Abe S; Tansho S; Suzuki D; Yamaguchi H; Hoshino E
    Kansenshogaku Zasshi; 2001 Feb; 75(2):137-43. PubMed ID: 11260880
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the L-dopa transport system in human epidermal Langerhans cells by omeprazole and its analogues.
    Bendsoe N; Ronquist G
    Amino Acids; 2004 Feb; 26(1):19-26. PubMed ID: 14752612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endogenous gastrin stimulates regeneration of remnant pancreas after partial pancreatectomy.
    Kim SW; Kim KH; Park SJ; Her HH; Jang JY; Park YH
    Dig Dis Sci; 2001 Oct; 46(10):2134-9. PubMed ID: 11680587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluorometric screening for metabolism-based drug--drug interactions.
    Crespi CL; Stresser DM
    J Pharmacol Toxicol Methods; 2000; 44(1):325-31. PubMed ID: 11274899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of pharmacokinetic interaction between omeprazole or lansoprazole and ivabradine in healthy volunteers: an open-label, randomized, crossover, pharmacokinetic interaction clinical trial.
    Portolés A; Calvo A; Terleira A; Laredo L; Resplandy G; Gorostiaga C; Moreno A
    J Clin Pharmacol; 2006 Oct; 46(10):1195-203. PubMed ID: 16988209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lansoprazole, a proton pump inhibitor, reduces the severity of indomethacin-induced rat enteritis.
    Kuroda M; Yoshida N; Ichikawa H; Takagi T; Okuda T; Naito Y; Okanoue T; Yoshikawa T
    Int J Mol Med; 2006 Jan; 17(1):89-93. PubMed ID: 16328016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The proton pump inhibitor lansoprazole inhibits rhinovirus infection in cultured human tracheal epithelial cells.
    Sasaki T; Yamaya M; Yasuda H; Inoue D; Yamada M; Kubo H; Nishimura H; Sasaki H
    Eur J Pharmacol; 2005 Feb; 509(2-3):201-10. PubMed ID: 15733557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Coadministration of lansoprazole and naproxen does not affect the pharmacokinetic profile of methotrexate in adult patients with rheumatoid arthritis.
    Vakily M; Amer F; Kukulka MJ; Andhivarothai N
    J Clin Pharmacol; 2005 Oct; 45(10):1179-86. PubMed ID: 16172183
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Omeprazole alleviates benzo[a]pyrene cytotoxicity by inhibition of CYP1A1 activity in human and mouse hepatoma cells.
    Shiizaki K; Ohsako S; Kawanishi M; Yagi T
    Basic Clin Pharmacol Toxicol; 2008 Nov; 103(5):468-75. PubMed ID: 18793272
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.